Adjuvant treatment of 126 cases of stage Ⅰb、Ⅱa cervical carcinoma after radical hysterectomy and pelvic lymphadenectomy / 中国癌症杂志

ABSTRACT

Purpose:To investigate the rational choice of adjuvant treatment and its clinical value for stage Ⅰb, Ⅱa cervical cancinoma after radical hysterectomy and pelvic lymphadenectomy.Methods:126 patients with stage Ⅰb and Ⅱa cervical cancer received adjuvant radiotherapy and/or chemotherapy after radical hysterectomy and pelvic lymphadenectomy .Of these patients, 64 received radiotherapy only, 26 chemotherapy only, 36 had both. The prognostic factors and treatment results were analyzed.Results:The overall 5-year survival rate for the 126 patients was 73%(92/126). For the radiotherapy only, chemotherapy only, and the radio-chemotherapy groups, the 5-year survival rates were 76.6%(49/64), 69.2%(18/26), and 69.4%(25/36) respectively. The clinical stages and the number of pelvic lymphnodes metastases were the most important prognostic factors. Conclusions:The value of adjuvant treatment for early stage cervical cancer after radical surgery was limited, but for patients who had more than two high risk factors, adjuvant treatment should be given, and at the same time, we should emphasis the importance of thoroughness of radical hysterectomy and pelvic lymphadenectomy.